DTC is usually treated with surgery, followed by the removal of the remaining thyroid tissues with radioiodine. However, approximately 5% to 15% of cases are resistant to radioiodine treatment, with these patients carrying a life expectancy of only three to five years from the time metastatic lesions are detected.
Previously, Exelixis announced that a clinical trial evaluating Cabometyx in this tough-to-treat population met one of the two primary endpoints of significant improvement versus placebo in progression-free survival (PFS).
